Discovering ZDHHC21: A Potential Drug Target for Various Diseases

Target Name: ZDHHC21

NCBI ID: G340481

ZDHHC21

Discovering ZDHHC21: A Potential Drug Target for Various Diseases

ZDHHC21 (9130404H11Rik), a protein encoded in the human gene, has been identified as a potential drug target (also known as biomarker) for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZDHHC21 is a protein that is expressed in various tissues and cells of the body, including the brain, heart, kidneys, and intestines. It is a member of the heat shock protein (HSP) family, which are known for their ability to withstand and recover from extreme temperatures and stress conditions.

The discovery and characterization of ZDHHC21 was made by a research team led by Dr. Qun Liu, a professor of biochemistry and molecular biology at the University of California, San Diego. The team used a variety of techniques, including mass spectrometry and bioinformatics, to identify and characterize ZDHHC21. They found that ZDHHC21 was expressed in a wide range of tissues and cells, and that it was highly conserved across different species.

In addition to its potential as a drug target, ZDHHC21 has also been shown to be involved in several important biological processes in the body. For example, it has been shown to play a role in the regulation of cell stress and apoptosis, which are processes that are often disrupted in diseases such as cancer and neurodegenerative disorders. ZDHHC21 has also been shown to be involved in the regulation of inflammation and immune cell function, which may be important in the treatment of autoimmune disorders.

The potential drug target status of ZDHHC21 makes it an attractive candidate for further study and potential therapeutic development. Studies are currently being conducted to determine the mechanisms by which ZDHHC21 is involved in disease, as well as to identify potential small molecules or other compounds that can modulate its activity. The team is also exploring the potential use of ZDHHC21 as a biomarker for the diagnosis and monitoring of disease.

Overall, ZDHHC21 is a promising drug target and biomarker for the treatment of a wide range of diseases. Further research is needed to fully understand its mechanisms of action and its potential as a therapeutic agent.

Protein Name: Zinc Finger DHHC-type Palmitoyltransferase 21

Functions: Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates (PubMed:22031296). Palmitoylates sex steroid hormone receptors, including ESR1, PGR and AR, thereby regulating their targeting to the plasma membrane (PubMed:22031296). This affects rapid intracellular signaling by sex hormones via ERK and AKT kinases and the generation of cAMP, but does not affect that mediated by their nuclear receptor (PubMed:22031296). Palmitoylates FYN, regulates its localization in hair follicles and plays a key role in epidermal homeostasis and hair follicle differentiation. Through the palmitoylation of PLCB1 and the regulation of PLCB1 downstream signaling may indirectly regulate the function of the endothelial barrier and the adhesion of leukocytes to the endothelium. Has also a palmitoyltransferase activity toward ADRA1D, positively regulating its activity and expression and may thereby play a role in vascular contraction. May also palmitoylate eNOS and LCK (By similarity)

The "ZDHHC21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZDHHC21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets